TP53 and non-small cell lung carcinoma: Taken together, even though our results on this topic could be affected by the limited numbers and should be considered mainly hypothesis-generating, they confirm the aggressiveness of TP53 and KRAS mutated NSCLC, while data on their predictive value to immunotherapy remains elusive.